Arthneeti
SG

Shree Ganesh Remedies Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Q1 FY27: Revenue ₹14.36 Cr, PAT ₹1.12 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Based on Shree Ganesh Remedies Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹677
Market cap₹896 Cr
P/E58.0

The short version

Q1FY27 Revenue from Operations: ₹14.36 Cr - YoY Change in Revenue: -42% - QoQ Change in Revenue: -57% - Total Income for Q1FY27: ₹15.30 Cr (down 40% YoY) - EBITDA for Q1FY27: ₹3.35 Cr (down 54% YoY) - PAT for Q1FY27: ₹1.12 Cr (down 68% YoY) - EPS for Q1FY27: ₹0.87 (down 68% YoY) Outlook: - European demand remains subdued with customers deferring orders amid geopolitical uncertainty and raw material volatility. Q1FY27 EBITDA: ₹3.35 Cr, down 54% YoY - Q1FY27 Operating Margin (EBITDA %): 23.3%, down 624 basis points YoY - Q1FY27 Profit After Tax (PAT): ₹1.12 Cr, down 68% YoY - Year-on-year changes: Revenue down 42%, EBITDA down 54%, PAT down 68% - Management notes subdued demand and expects order volumes to restore over a couple of quarters with a meaningful improvement anticipated in H2FY27.

From Shree Ganesh Remedies Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Q1FY27 Revenue from Operations: ₹14.36 Cr - YoY Change in Revenue: -42% - QoQ Change in Revenue: -57% - Total Income for Q1FY27: ₹15.30 Cr (down 40% YoY) - EBITDA for Q1FY27: ₹3.35 Cr (down 54% YoY) - PAT for Q1FY27: ₹1.12 Cr (down 68% YoY) - EPS for Q1FY27: ₹0.87 (down 68% YoY) **Outlook:** - European demand remains subdued with customers deferring orders amid geopolitical uncertainty and raw material volatility. - Marketing and manufacturing agreement with EU distributor ended; transitioning to direct customer engagement expected to restore volumes in a few quarters. - CRAMS projects in South-East Asia expected to start contributing from H2FY27.

2 more points from Shree Ganesh Remedies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Dahej Land Acquisition (2022): Acquired 40,554 sq m land for ₹11 crores for future large-scale projects; phased expansion planned; common infrastructure and warehousing under construction; multiple projects under evaluation.
  • Ankleshwar Site Expansion:
  • Unit 1 has 7 functional production blocks; Block 8 completed in FY25.
  • Block 7 under commissioning, expected H1FY27, with projected CAPEX of ~₹20 crores (₹15 crores planned for FY26).
  • Ongoing CAPEX for Plant 7 and commissioning of new Pilot Plant with automation and flow chemistry slated for Q4 FY26.

2 more points from Shree Ganesh Remedies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides insights related to demand and customer engagements: - European demand remained subdued in Q1FY27 with customers deferring orders due to geopolitical uncertainty and raw material price volatility. - Marketing and manufacturing agreement with an EU distributor was terminated due to non-performance, opening direct customer engagement opportunities expected to restore volumes over a couple of quarters.

2 more points from Shree Ganesh Remedies Ltd's call on order book

Create a free account to keep reading this call

Shree Ganesh Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shree Ganesh Rem's management said in earlier quarters

Earlier calls (1)

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shree Ganesh Remedies Ltd Q1 FY27 results?

Q1FY27 Revenue from Operations: ₹14.36 Cr - YoY Change in Revenue: -42% - QoQ Change in Revenue: -57% - Total Income for Q1FY27: ₹15.30 Cr (down 40% YoY) - EBITDA for Q1FY27: ₹3.35 Cr (down 54% YoY) - PAT for Q1FY27: ₹1.12 Cr (down 68% YoY) - EPS for Q1FY27: ₹0.87 (down 68% YoY) Outlook: - European demand remains subdued with customers deferring orders amid geopolitical uncertainty and raw material volatility. Q1FY27 EBITDA: ₹3.35 Cr, down 54% YoY - Q1FY27 Operating Margin (EBITDA %): 23.3%, down 624 basis points YoY - Q1FY27 Profit After Tax (PAT): ₹1.12 Cr, down 68% YoY - Year-on-year changes: Revenue down 42%, EBITDA down 54%, PAT down 68% - Management notes subdued demand and expects order volumes to restore over a couple of quarters with a meaningful improvement anticipated in H2FY27.

What is Shree Ganesh Remedies Ltd share price analysis?

Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shree Ganesh Remedies Ltd planning capital expenditure?

Dahej Land Acquisition (2022): Acquired 40,554 sq m land for ₹11 crores for future large-scale projects; phased expansion planned; common infrastructure and warehousing under construction; multiple projects under evaluation.

Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.